Published in NeuroRx on July 01, 2005
Cathepsin D--many functions of one aspartic protease. Crit Rev Oncol Hematol (2008) 2.26
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun (2013) 1.45
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid Med Cell Longev (2012) 1.08
Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast (2011) 1.06
Are tangles as toxic as they look? J Mol Neurosci (2011) 1.05
Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models. PLoS One (2011) 1.01
Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm (Vienna) (2011) 0.99
Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis (2010) 0.98
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol (2014) 0.96
Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis (2013) 0.96
Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. Mol Cell Biol (2011) 0.94
Ocular manifestations of Alzheimer's disease in animal models. Int J Alzheimers Dis (2012) 0.94
A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death. Int J Alzheimers Dis (2011) 0.93
Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? Age (Dordr) (2011) 0.92
Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int (2013) 0.89
APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neurosci Biobehav Rev (2012) 0.89
Changes in neurogenesis in dementia and Alzheimer mouse models: are they functionally relevant? Eur Arch Psychiatry Clin Neurosci (2007) 0.88
Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J (2015) 0.88
On cognitive ecology and the environmental factors that promote Alzheimer disease: lessons from Octodon degus (Rodentia: Octodontidae). Biol Res (2016) 0.87
Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimers Res Ther (2012) 0.87
The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb Blood Flow Metab (2008) 0.86
Beyond the rat models of human neurodegenerative disorders. Cell Mol Neurobiol (2009) 0.86
Neurologic and motor dysfunctions in APP transgenic mice. Rev Neurosci (2012) 0.85
Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease. Am J Pathol (2011) 0.85
Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? Expert Rev Neurother (2006) 0.84
Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics (2007) 0.83
Lithium suppresses Aβ pathology by inhibiting translation in an adult Drosophila model of Alzheimer's disease. Front Aging Neurosci (2014) 0.82
The rat as an animal model of Alzheimer's disease. J Cell Mol Med (2009) 0.82
Molecular brain imaging in the multimodality era. J Cereb Blood Flow Metab (2012) 0.81
Area-specific alterations of synaptic plasticity in the 5XFAD mouse model of Alzheimer's disease: dissociation between somatosensory cortex and hippocampus. PLoS One (2013) 0.80
Brain ischemia and ischemic blood-brain barrier as etiological factors in sporadic Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.79
Fishy business: effect of omega-3 fatty acids on zinc transporters and free zinc availability in human neuronal cells. Nutrients (2014) 0.78
Delayed dendritic development in newly generated dentate granule cells by cell-autonomous expression of the amyloid precursor protein. Mol Cell Neurosci (2013) 0.78
Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary Tangles and Results in Cognitive Impairment During Normal Aging. Neurochem Res (2016) 0.78
Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner. Int J Alzheimers Dis (2010) 0.77
Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau₄₅₋₂₃₀ transgenic mice. Neuroscience (2014) 0.77
Screening pesticides for neuropathogenicity. J Biomed Biotechnol (2006) 0.76
Mechanical Stress as the Common Denominator between Chronic Inflammation, Cancer, and Alzheimer's Disease. Front Oncol (2015) 0.76
Correlated inflammatory responses and neurodegeneration in peptide-injected animal models of Alzheimer's disease. Biomed Res Int (2014) 0.76
Behavioral stress fails to accelerate the onset and progression of plaque pathology in the brain of a mouse model of Alzheimer's disease. PLoS One (2013) 0.75
Tibetan medicine "RNSP" in treatment of Alzheimer disease. Int J Clin Exp Med (2015) 0.75
Dysregulation of Autophagy, Mitophagy, and Apoptotic Genes in the Medial Temporal Lobe Cortex in an Ischemic Model of Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies. Cell Mol Neurobiol (2009) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology (1993) 14.54
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 10.36
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science (1987) 8.29
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun (1984) 8.14
The medial temporal lobe memory system. Science (1991) 7.86
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging (1997) 7.54
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7.07
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol (1990) 6.79
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 6.62
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A (1997) 5.66
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci U S A (1985) 4.97
Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron (2003) 4.70
Paired helical filaments in electron microscopy of Alzheimer's disease. Nature (1963) 4.62
BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci (2001) 4.54
Life and death of neurons in the aging brain. Science (1997) 4.52
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
Plaques, tangles and dementia. A quantitative study. J Neurol Sci (1982) 4.52
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
Skeletal and CNS defects in Presenilin-1-deficient mice. Cell (1997) 4.50
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell (2002) 4.37
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett (1992) 4.29
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (2001) 4.25
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol (1988) 4.10
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.07
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (1999) 3.96
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci (1999) 3.85
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet (1994) 3.67
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology (2003) 3.62
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A (1995) 3.36
Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature (1995) 3.33
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci (1996) 3.26
Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch Neurol (1989) 3.24
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
A familial Alzheimer's disease locus on chromosome 1. Science (1995) 3.14
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A (1999) 2.82
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci (1985) 2.72
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci (1996) 2.69
Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron (2001) 2.62
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.43
Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem (2001) 2.40
Neuron loss in APP transgenic mice. Nature (1998) 2.38
Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol (1986) 2.33
Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron (2002) 2.28
Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature (2003) 2.28
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
New frontiers in Alzheimer's disease genetics. Neuron (2001) 2.17
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci U S A (1985) 2.16
APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A (2002) 2.16
Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol (1999) 2.12
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 2.07
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A (2003) 8.92
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci (2005) 4.71
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol (2002) 4.42
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (2013) 3.59
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (2002) 3.48
Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron (2008) 3.46
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem (2003) 3.00
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol (2006) 2.93
Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry (2004) 2.70
Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science (2009) 2.65
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron (2004) 2.53
Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 2.47
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord (2003) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem (2005) 2.08
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci (2004) 1.99
Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci (2009) 1.99
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J (2010) 1.90
Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry (2007) 1.88
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem (2005) 1.85
Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci (2003) 1.85
Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci (2006) 1.83
Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proc Natl Acad Sci U S A (2003) 1.81
Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci (2003) 1.81
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett (2002) 1.79
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci (2008) 1.77
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol (2003) 1.73
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci (2005) 1.70
Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol (2007) 1.69
Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci (2009) 1.68
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. J Cell Biol (2009) 1.68
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J (2006) 1.66
Inhibition of the NFAT pathway alleviates amyloid β neurotoxicity in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.64
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun (2009) 1.63
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl (2005) 1.60
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci (2006) 1.59
The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res (2005) 1.57
Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain (2007) 1.55
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem (2007) 1.55
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
BACE is degraded via the lysosomal pathway. J Biol Chem (2005) 1.53
Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol (2013) 1.52
Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 1.51
Fluorescence resonance energy transfer determinations using multiphoton fluorescence lifetime imaging microscopy to characterize amyloid-beta plaques. J Biomed Opt (2003) 1.47
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Simultaneous multispectral reflectance imaging and laser speckle flowmetry of cerebral blood flow and oxygen metabolism in focal cerebral ischemia. J Biomed Opt (2008) 1.46
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Alzheimer's disease: synapses gone cold. Mol Neurodegener (2011) 1.43
CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem (2008) 1.43
Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J (2002) 1.43
Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci (2008) 1.43
In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci (2003) 1.43
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci (2004) 1.40
Adult onset leukodystrophy with neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations. Brain Pathol (2008) 1.40
Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther (2009) 1.38
Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci U S A (2002) 1.36
The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol (2012) 1.36
Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J (2006) 1.35
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest (2009) 1.35